|Array To Report Top-line Results From ARRY-502 Asthma Trial; XOMA Completes Enrollment in Phase 2 Proof-of-Concept Gevokizumab Trial|
|By Staff and Wire Reports|
|Monday, 22 July 2013 20:06|
Array BioPharma Inc. (Nasdaq: ARRY) will report top-line results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to discuss those results on Tuesday, July 23, 2013. Ron Squarer, Chief Executive Officer, will lead the call.
Conference Call Information Date: Tuesday, July 23, 2013 Time: 9:00 a.m. eastern time Toll-Free: (888) 771-4371 Toll: (847) 585-4405 Pass Code: 35320183 Webcast, including Replay and Conference Call Slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome
XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, confirmed it has completed patient enrollment in the Company's Phase 2 proof-of-concept (POC) study designed to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with active inflammatory, erosive osteoarthritis of the hand (EOA) and elevated C-reactive protein (CRP) levels. XOMA's study enrolled approximately 90 patients who were randomized 2:1 to receive 60mg of gevokizumab dosed subcutaneously once monthly or placebo. The study was designed and powered to detect a significant improvement from baseline versus placebo in the mean Australian/Canadian Hand Osteoarthritis Index (AUSCAN™) pain score in the target hand at Day 84. The study also is capturing multiple outcome measures, including pain, stiffness, physical function, X-ray, radiographic and MRI changes, as well as changes in CRP and concomitant acetaminophen use, at three and six months. The Company anticipates having preliminary top-line data for the AUSCAN score in October.
XOMA also provided an update on the EOA study in patients with non-elevated CRP. This study was opened for enrollment in May, and investigators have enrolled approximately 40 patients of the targeted 90 who had qualified for the original EOA study with the exception that they did not have elevated CRP levels. This supplemental study will help inform the design of the potential Phase 3 studies of gevokizumab in EOA.
ALR Technologies Inc. (OTCBB: ALRT) released onto its website a recording of a Webinar conducted by Dr. Kent Stoneking, ALRT's Director of Diabetes Care Facilitation, discussing the results of a recent clinical trial comparing an Internet-based Glucose Monitoring System (IBGMS) with a Continuous Glucose Monitoring System (CGMS).
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2013 financial results on Wednesday, August 7, 2013, before the market opens.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.
Foster Wheeler AG (Nasdaq: FWLT) announced today that a subsidiary of its Global Engineering and Construction (E&C) Group has signed an equity purchase agreement with CEFOC (The Fourth Construction Company Ltd. of China Electronics System Engineering) to purchase a 49% share in its Chinese Design Institute, PECHDI.
Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved the first research milestone in its collaboration with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), which was announced in January 2013.
Insmed Incorporated (NASDAQ: INSM) today announced the closing of a $71.8 million underwritten public offering of 6,900,000 shares of common stock, including 900,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of $10.40 per share to the public.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the enrollment of its first patient in a Phase 2 clinical trial of its bispecific antibody, MM-111, for the treatment of advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers.
MMRGlobal, Inc. (OTCQB: MMRF), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals, today announced that through its independent sales and marketing agreement with Healthcare Merchant Solutions ("HMS"), the Company has expanded sales of its products and services to affinity organizations, retailers, multilevel marketers, membership organizations, banks and credit card companies as well as non-profits.
NanoViricides, Inc. (OTC BB: NNVC) announced today that it has been notified that the Committee on Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA) has appointed a team of clinical coordinators for the purpose of reviewing the Company’s upcoming orphan drug designation application for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
NeoStem, Inc. (NYSE MKT:NBS), a leader in the emerging cellular therapy market, announced today the appointment of Stephen W. Potter as Executive Vice President of the Company.
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announced interim immune response data from the company’s Phase II study of ImmunoPulse in patients with metastatic melanoma.
PetMed Express, Inc. (Nasdaq:PETS) today announced its financial results for the quarter ended June 30, 2013. Net sales for the quarter ended June 30, 2013 were $74.2 million, compared to $69.0 million for the quarter ended June 30, 2012, an increase of 7.6%.
Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Dennis J. Selkoe, MD to its Board of Directors.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has received a positive opinion from the European Union (EU) Committee for Orphan Medicinal Products (COMP) recommending orphan drug exclusivity for PROCYSBI® (mercaptamine) gastro-resistant hard capsules for the treatment of proven nephropathic cystinosis.
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Erle T. Mast as a director of the Company.
Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that its second Phase 3 efficacy study for SFP, called CRUISE-2, has completed patient dosing.
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has filed an application for listing on The NASDAQ Capital Market.
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has completed a 14-month collaborative project with Bayer HealthCare, a subgroup of Bayer AG, to improve prediction of ionization constants for drug-like molecules.
Sino Bioenergy Corp. (OTC Pink:SFBE) (Borse Berlin:3SF) today updated its shareholders on its current rice harvest and Cambodian MOU.
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the 2013 InvestMNt conference on Thursday, August 1, 2013, at 8:30 a.m. CT (9:30 a.m. ET) in Minneapolis, MN.
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) announced today its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.
TheDirectory.com, Inc. (PINKSHEETS: SEEK) an emerging leader in the Local search space, today announced that it has engaged New Jersey based financial advisory firm Gibraltar Advisors to assist the Company in the area of mergers and acquisitions, corporate financing and deal structuring.
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today confirmed it has completed patient enrollment in the Company's Phase 2 proof-of-concept (POC) study designed to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with active inflammatory, erosive osteoarthritis of the hand (EOA) and elevated C-reactive protein (CRP) levels.